// App-Quantinova.ai

8008 : A phase I/II study of ixazomib (Ix) pomalidomide (POM) dexamethasone (DEX) in relapsed refractory (R/R) multiple myeloma: Initial results.

Researchers

Presenter

  • Amrita Y. Krishnan

Principal Investigators

  • Prashant Kapoor

  • Joycelynne Palmer

  • Shaji Kumar

  • Sagar Lonial

  • Myo Htut

  • Chatchada Karanes

  • Nitya Nathwani

  • Michael Alan Rosenzweig

  • Firoozeh Sahebi

  • George Somlo

  • Lupe Duarte

  • Stephen J. Forman

  • Jesus G. Berdeja

Medical Centers

  • City of Hope, Duarte, CA

  • Division of Medical Oncology, Mayo Clinic, Rochester, MN

  • Winship Cancer Institute of Emory University, Atlanta, GA

  • City Of Hope, Arcadia, CA

  • City of Hope, Judy and Bernard Briskin Center for Myeloma, Duarte, CA

  • Kaiser Permanente Southern California, Duarte, CA

  • Division of Biostatistics, City of Hope National Medical Center, Duarte, CA

  • Sarah Cannon Research Institute, Nashville, TN

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Peripheral neuropathy

  • Multiple Myeloma

Biomarkers

  • N/A

Drug/Treatment

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Pomalidomide

  • CC-4047

  • Ixazomib

Outcome

  • N/A

Study Design

  • N/A

Phase

  • I/II

Study Id's

  • NCT02119468

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved